Evidence map›Paper›PMID 42177184›Full record

ArticleCell death discovery2026

A kidney-protective mechanism via cellular oxidative stress reduction induced by CD5L protein.

Kai Kudo, Takashi Ikeda, Kazutaka Ikeda, Natsumi Maehara, Aika Hirota, Yuri Yoshikawa, Haruka Mori, Masumi Takayama, Keisuke Yasuda, Tetsushi Tezuka and 3 more

Abstract read
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kai KudoThe Institute for AIM Medicine (IAM), Tokyo, Japan.ORCID http://orcid.org/0000-0002-5410-3334
Takashi IkedaThe Institute for AIM Medicine (IAM), Tokyo, Japan.
Kazutaka IkedaDepartment of Applied Genomics, Laboratory of Biomolecule Analysis, Kazusa DNA Research Institute, Chiba, Japan.
Natsumi MaeharaThe Institute for AIM Medicine (IAM), Tokyo, Japan.
Aika HirotaThe Institute for AIM Medicine (IAM), Tokyo, Japan.
Yuri YoshikawaThe Institute for AIM Medicine (IAM), Tokyo, Japan.
Haruka MoriThe Institute for AIM Medicine (IAM), Tokyo, Japan.
Masumi TakayamaThe Institute for AIM Medicine (IAM), Tokyo, Japan.
Keisuke YasudaThe Institute for AIM Medicine (IAM), Tokyo, Japan.
Tetsushi TezukaThe Institute for AIM Medicine (IAM), Tokyo, Japan.
Toshio TakagiDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Satoko AraiThe Institute for AIM Medicine (IAM), Tokyo, Japan. arai.satoko@iamaim.jp.
Toru MiyazakiThe Institute for AIM Medicine (IAM), Tokyo, Japan. tm@iamaim.jp.ORCID http://orcid.org/0000-0003-3842-4362

Funding

Japan Agency for Medical Research and Development (AMED) 23gm0010006hMEXT | Japan Society for the Promotion of Science (JSPS) 20H03446MEXT | Japan Society for the Promotion of Science (JSPS) 21H05122
6 · The paper itself

Abstract

Chronic kidney disease (CKD) encompasses multiple pathogenic mechanisms manifested by inflammation, fibrosis, oxidative stress and cell death. We previously showed that circulating protein CD5L (or AIM) ameliorates acute kidney injury, so we explored its effect in a mouse model of unilateral ureteral obstruction (UUO)-induced renal fibrosis. Here, we show a unique kidney-protective pathway mediated by CD5L. CD5L is endocytosed into renal epithelial cells, where it reduces oxidative stress, decreasing cell injury and death. This effect is supported by both a cysteine-dependent direct antioxidant activity of CD5L and enhancement of Nrf2-associated antioxidant responses. In addition, our data suggest that suppression of sphingomyelinase activity and reduction of cellular ceramide may contribute, at least in part, to CD5L-associated augmentation of Nrf2 nuclear transport. These effects depend on the reactive cysteine residue on the CD5L surface. Consistent with these findings, recombinant CD5L treatment in UUO mice reduces sphingomyelinase activity, activates Nrf2, and lowers oxidative stress, alleviating inflammation, fibrosis, and kidney injury. Our findings uncover a novel antioxidant pathway mediated by CD5L with potential implications for CKD-associated fibrotic mechanisms.

Identifiers

PMID42177184
PMCPMC13377098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.